$Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study$
QR Code

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study

Background. The treatment options for patients with multiple myeloma who refractory to previous bortezomib and lenalidomide therapy are limited. Pomalidomide is ап immunomodulatory agent that was registered for the treatment of patients with double refractory multiple myeloma.Aim. To evaluate effica...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. G. Potapenko, E. V. Baumert, A. A. Bobrova, R. V. Vashchenkov, N. V. Dorofeeva, K. D. Kaplanov, E. V. Karyagina, A. N. Levanov, A. S. Luchinin, S. I. Moiseev, A. V. Novitskii, A. S. Nizamutdinova, О. V. Pirogova, S. A. Povzun, М. V. Platonov, V. V. Porunova, D. А. Ptashnikov, V. V. Ryabchikova, S. Ya. Simeniv, I. А. Skorokhod, Е. А. Ukrainchenko, D. А. Chaginskaya, T. V. Shelekhova, M. N. Shirokova, A. A. Shutylev, N. V. Medvedeva
Format:	Article
Language:	Russian
Published:	ABV-press 2022-07-01
Series:	Онкогематология
Subjects:	multiple myeloma pomalidomide double refractory triplet lenalidomide bortezomib
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/558
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study

Similar Items